{
  "docId": "019de076-8eed-77e6-97e7-f406514b962a",
  "docSlug": "e8bbfe027845ab55cba77860ad12e49b",
  "documentTitle": "Absci | Investor Conference Presentation Deck | 22 slides",
  "authorId": "absci",
  "authorName": "Absci",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 22,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8eed-77e6-97e7-f406514b962a/3",
  "deckHref": "/decks/019de076-8eed-77e6-97e7-f406514b962a",
  "deckJsonHref": "/decks/019de076-8eed-77e6-97e7-f406514b962a.json",
  "deckAnchorHref": "/decks/019de076-8eed-77e6-97e7-f406514b962a#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.52,
        "y": 0.56
      },
      "kind": "list",
      "text": "10 NEW ACTIVE PROGRAMS: Achieved guidance for 2023 with growing partnership momentum for 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b19c21d1-1015-4f6a-9428-f5bb6e67cf47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.52,
        "y": 0.26
      },
      "kind": "list",
      "text": "NEW PHARMA PARTNERSHIPS: AstraZeneca Types up $247m Al-enabled Oncology Antibody Design Pact; Skin in the Game: Absci Partners with Almirall on Up-to-$650M Dermatology AI Collaboration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b28c2f8f-d401-47eb-a27f-052dfe378ca5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.75
      },
      "kind": "list",
      "text": "INTERNAL ASSET PORTFOLIO: Internal Asset Portfolio focused on cytokine biology; Lead asset ABS-101, an AI-designed TL1A antibody product candidate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f777c900-0cc5-4058-ad18-cc5528452f89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.43
      },
      "kind": "paragraph",
      "text": "Our Integrated AI & Wet Lab Platform Aims to Engineer Better Biologics Faster at Lower Cost with Design-in Functionality and Best-in-Class Properties",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b47f55fd-b1e8-49e2-ae4f-5f3fb3b14a3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.52,
        "y": 0.15
      },
      "kind": "title",
      "text": "RECENT SUCCESSES",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d04dfb4f-363f-4fb5-aa7f-702ee684f57b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Absci is a Data-First Generative AI Drug Creation Company",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2e74b23-87b9-4eca-9e47-e677050e8b53",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "2c2d4c37-974a-49c2-a93d-b2a78ac19b37",
      "evidence": "This slide is labeled as 'executive_summary' and contains a summary of the company's recent successes and portfolio.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 1,
      "beatId": "7fc65cc8-daeb-4193-9e6d-6f51b7adb94f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The presentation starts by highlighting the inefficiencies of current drug creation methods.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1f831aed-0458-4598-bd35-2935d77a97d3",
      "evidence": "The presentation highlights the limitations and costs of traditional methods.",
      "position": 0,
      "objective": "What is the cost of not adopting AI in drug creation?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}